Peking University Cancer Hospital
北京大学肿瘤医院
Peking University Cancer Hospital is a leading oncology center in China that has served as a clinical research partner for microbiome drug developer XUnknown (未知君) . In what XUnknown described as the world's first and largest study of its kind, the hospital collaborated on a clinical trial testing fecal microbiota transplant capsules to enhance PD-1/PD-L1 immunotherapy efficacy in gastrointestinal cancer patients . The hospital was also named among several prominent institutions—alongside Peking Union Medical College Hospital and Nanfang Hospital—that partnered with XUnknown on clinical programs across its pipeline of first-in-class microbiome drugs as of 2021 .
AI-generated — may contain errors, please verify.
Coverage
Unknown Closes Nearly $100 Million in Series B Funding, Launches AI×BT Strategy
Focused on gut microbiome AI-driven drug discovery, with self-developed drug candidates already in registrational clinical trials.
5Y News | AI Microbiome Drug Developer "Unknown" Closes Nearly $100 Million Series B Financing
Launching a new AI×BT strategy.
5Y News｜Unknown Closes Tens of Millions of Dollars in Series B+ Funding to Advance Microbiome Drug Clinical Trials
Leading domestic microbiome therapeutics company Unknown has recently completed a tens-of-millions-of-dollars Series B+ funding round, with continued backing from 5Y Capital.
China's First AI Microbiome Drug Company "Unknown" Raises Nearly $10 Million in Funding
Leveraging AI and bioengineering technologies to deliver precision management of gut health for Chinese consumers.
